Four research-based biopharmaceutical companies–MSD, Novartis, Pfizer, and Sanofi–together with committed governments and other stakeholders, including the Bill & Melinda Gates Foundation–established the Access and Affordability Initiative (AAI), which focuses on differential, or tiered, pricing, in which people pay according to their means.
In pilot studies in Ghana and the Philippines, thousands of patients who face affordability barriers will be provided with differentially discounted prices for medicines to treat NCDs such as cardiovascular conditions, type 2 diabetes, hypertension, pre-eclampsia, childhood pneumonia and, in a small number of patients in Ghana, some cancers.When the studies conclude in mid-2017, a team from Johns Hopkins University will measure the extent to which the approach is effective and sustainable. The companies will then decide whether to introduce differential pricing for NCD medicines on a wider scale in Ghana and the Philippines, or in other markets.
"While access to medicines is a complex, multifaceted challenge, improving the affordability of medicines is part of the solution."
for more information